← Leaderboards
Peter Lindsay Anderson
University Of Washington
$21,683,918
Attributed
$25,216,282
Total exposure
12
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$25,216,282 · 12
By mechanism
R01$15,239,003 · 6
U01$7,080,654 · 2
U19$2,229,518 · 1
S10$399,840 · 1
R03$151,767 · 1
R34$115,500 · 1
Top collaborators
- Benjamin H Chi5 shared
- Lynda Stranix-Chibanda5 shared
- Kenneth Kiggundu Mugwanya4 shared
Most similar at University Of Washington
Same institution · by research overlap
- Mary L. Disis$210,448,010
- Katharine Anthony Bradley$17,650,205
- Dennis M Donovan$35,213,977
- Grace C John-Stewart$42,921,726
- Kris Kowdley$16,222,064
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsDoseFuturePharmacologyDrug KineticsAids PreventionPlasmaTenofovirDiphosphatesHiv InfectionsBaseBloodSamplingMeasurementEmtricitabineMonitorParticipantSitePeripheral Blood Mononuclear CellTissuesWomanLaboratoriesSafetyAdherence
Grant awards (42)
Optimizing PrEP regimens for pregnant women in sub-Saharan Africa$667,548
R01 · FY2025 · AI
A platform for monitoring the efficacy and optimal dosing of long-acting ART$630,573
R01 · FY2025 · AI · contact PI
PrEP adherence-concentration thresholds associated with HIV protection among African women$731,299
R01 · FY2024 · AI
A platform for monitoring the efficacy and optimal dosing of long-acting ART$653,182
R01 · FY2024 · AI · contact PI
Optimizing PrEP regimens for pregnant women in sub-Saharan Africa$300,000
R01 · FY2024 · AI
PrEP adherence-concentration thresholds associated with HIV protection among African women$858,195
R01 · FY2023 · AI
A platform for monitoring the efficacy and optimal dosing of long-acting ART$685,453
R01 · FY2023 · AI · contact PI
New Pharmacologic Measures of ART Adherence and Exposure: Pathway to Clinical Implementation$665,566
R01 · FY2023 · AI · contact PI
Optimizing PrEP regimens for pregnant women in sub-Saharan Africa$632,461
R01 · FY2023 · AI
PrEP adherence-concentration thresholds associated with HIV protection among African women$754,770
R01 · FY2022 · AI
Optimizing PrEP regimens for pregnant women in sub-Saharan Africa$691,647
R01 · FY2022 · AI
New Pharmacologic Measures of ART Adherence and Exposure: Pathway to Clinical Implementation$687,142
R01 · FY2022 · AI · contact PI
A platform for monitoring the efficacy and optimal dosing of long-acting ART$676,949
R01 · FY2022 · AI · contact PI
PrEP adherence-concentration thresholds associated with HIV protection among African women$749,434
R01 · FY2021 · AI
Optimizing PrEP regimens for pregnant women in sub-Saharan Africa$686,617
R01 · FY2021 · AI
Novel approaches for quantitative assessment of adherence$710,897
R01 · FY2020 · AI · contact PI
Novel approaches for quantitative assessment of adherence$711,362
R01 · FY2019 · AI · contact PI
Core C - Pharmacokinetics$642,759
U19 · FY2019 · AI · contact PI
Novel approaches for quantitative assessment of adherence$720,771
R01 · FY2018 · AI · contact PI
Core C - Pharmacokinetics$379,744
U19 · FY2018 · AI · contact PI
Novel approaches for quantitative assessment of adherence$631,308
R01 · FY2017 · AI · contact PI
Core C - Pharmacokinetics$379,148
U19 · FY2017 · AI · contact PI
PrEP and ART adherence monitoring using dried blood spots$900,286
U01 · FY2016 · AI · contact PI
Novel approaches for quantitative assessment of adherence$649,135
R01 · FY2016 · AI · contact PI
Core C - Pharmacokinetics$367,802
U19 · FY2016 · AI · contact PI
PrEP and ART adherence monitoring using dried blood spots$683,429
U01 · FY2015 · AI · contact PI
Core C - Pharmacokinetics$460,065
U19 · FY2015 · AI · contact PI
PrEP and ART adherence monitoring using dried blood spots$655,715
U01 · FY2014 · AI · contact PI
PrEP and ART adherence monitoring using dried blood spots$649,049
U01 · FY2013 · AI · contact PI
Cellular pharmacology of tenofovir and emtricitabine for HIV prophylaxis$623,431
U01 · FY2012 · AI · contact PI
Cellular pharmacology of tenofovir and emtricitabine for HIV prophylaxis$2,159,561
U01 · FY2011 · AI · contact PI
Cellular pharmacology of tenofovir and emtricitabine for HIV prophylaxis$648,063
U01 · FY2010 · AI · contact PI
Cellular pharmacology of tenofovir and emtricitabine for HIV prophylaxis$761,120
U01 · FY2009 · AI · contact PI
Sex and disease dependent nucleoside analog toxicity$387,486
R01 · FY2009 · AI · contact PI
UPLC-MS for pharmacology studies in HIV$399,840
S10 · FY2008 · RR · contact PI
Sex and disease dependent nucleoside analog toxicity$322,953
R01 · FY2008 · AI · contact PI
Cellular pharmacology of tenofovir and emtricitabine for HIV prophylaxis$115,500
R34 · FY2008 · AI · contact PI
Sex and disease dependent nucleoside analog toxicity$330,232
R01 · FY2007 · AI · contact PI
Genetic-determinants of protease inhibitor pharmacology$74,767
R03 · FY2007 · AI · contact PI
Sex and disease dependent nucleoside analog toxicity$340,623
R01 · FY2006 · AI · contact PI
Genetic-determinants of protease inhibitor pharmacology$77,000
R03 · FY2006 · AI · contact PI
Sex and disease dependent nucleoside analog toxicity$363,400
R01 · FY2005 · AI